硫嘌呤停用对维得利珠单抗治疗的溃疡性结肠炎患者的影响:一项随机对照试验
这项多中心随机对照试验纳入维得利珠单抗联合硫嘌呤治疗且无激素临床缓解≥6个月、内镜缓解或改善(Mayo内镜子评分≤1)的溃疡性结肠炎患者,按2:1随机分为停用硫嘌呤组(42例)与继续硫嘌呤组(20例)。第48周维得利珠单抗谷浓度两组无显著差异,但继续组粪便钙卫蛋白缓解、组织学缓解及组织学-内镜缓解均显著高于停用组。
要点
- 停用硫嘌呤未显著影响第48周维得利珠单抗谷浓度(继续组14.7 μg/mL vs 停用组15.9 μg/mL,P=0.36)。
- 继续硫嘌呤组粪便钙卫蛋白缓解率显著高于停用组(95.0% vs 71.4%,P=0.03)。
- 组织学活动(HR 15.5)和既往抗肿瘤坏死因子暴露(HR 6.5)可预测停用硫嘌呤后的临床复发。
核心结论
- 停用硫嘌呤不影响维得利珠单抗谷浓度,但可能增加粪便钙卫蛋白、组织学及组织学-内镜活动。
- 组织学活动和既往抗肿瘤坏死因子暴露可能预测使用维得利珠单抗的溃疡性结肠炎患者停用硫嘌呤后的疾病复发。
研究设计与样本
- 多中心随机对照试验,招募接受维得利珠单抗300 mg每8周静脉给药联合硫嘌呤治疗的溃疡性结肠炎患者。
- 无激素临床缓解≥6个月且内镜缓解或改善(Mayo内镜子评分≤1)的患者按2:1随机分为停用硫嘌呤组(n=42)与继续硫嘌呤组(n=20)。
- 主要结局为比较第48周维得利珠单抗谷浓度。
主要发现
- 第48周维得利珠单抗谷浓度继续组为14.7 μg/mL(IQR 12.3-18.5 μg/mL),停用组为15.9 μg/mL(IQR 10.1-22.7 μg/mL),两组无显著差异(P=0.36)。
- 继续组粪便钙卫蛋白缓解率显著高于停用组(95.0%,19/20 vs 71.4%,30/42;P=0.03)。
- 继续组组织学缓解率显著高于停用组(80.0%,16/20 vs 48.6%,18/37;P=0.02)。
- 继续组组织学-内镜缓解率显著高于停用组(75.0%,15/20 vs 32.4%,12/37;P=0.002)。
- 组织学活动(HR 15.5;95%CI 1.6-146.5;P=0.02)和既往抗肿瘤坏死因子暴露(HR 6.5;95%CI 1.3-33.8;P=0.03)预测停用硫嘌呤后的临床复发。
关键数值与推荐
- 临床复发定义为部分Mayo评分≥3且粪便钙卫蛋白>150 μg/g,或Mayo内镜子评分较基线增加≥1。
- 粪便钙卫蛋白缓解定义为<150 μg/g;C反应蛋白缓解定义为<5 mg/L。
- 内镜缓解定义为中心判读的Mayo内镜子评分=0;组织学缓解定义为Nancy指数=0。
- 随机分组比例为2:1(停用组:继续组)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The impact of thiopurine de-escalation while on vedolizumab versus continuing thiopurine therapy in ulcerative colitis (UC) is unclear. We aimed to determine the effect of thiopurine withdrawal for patients with UC in remission on vedolizumab. METHODS: This multicenter randomized controlled trial recruited UC patients on vedolizumab 300 mg intravenously every 8 weeks and a thiopurine. Patients in steroid-free clinical remission for ≥6 months and endoscopic remission/improvement (Mayo endoscopic subscore ≤1) were randomized 2:1 to withdraw or continue thiopurine. Primary outcome was comparing week 48 vedolizumab trough concentrations. Secondary outcomes were clinical relapse (partial Mayo score ≥3 and fecal calprotectin >150 μg/g or increase in Mayo endoscopic subscore ≥1 from baseline), fecal calprotectin remission (<150 μg/g), C-reactive protein remission (<5 mg/L), centrally read endoscopic remission (Mayo endoscopic subscore = 0), histologic remission (Nancy index = 0), histo-endoscopic remission, and adverse events. RESULTS: In total, 62 patients were randomized to continue (n = 20) or withdraw (n = 42) thiopurine. At week 48, vedolizumab trough concentrations were not significantly different between continue and withdrawal groups (14.7 μg/mL, interquartile rate [IQR], 12.3-18.5 μg/mL versus 15.9 μg/mL, IQR, 10.1-22.7 μg/mL, respectively, P = 0.36). The continue group had significantly higher fecal calprotectin remission (95.0%, 19/20 versus 71.4%, 30/42; P = .03), histologic remission (80.0%, 16/20 versus 48.6%, 18/37; P = .02), and histo-endoscopic remission (75.0%, 15/20 versus 32.4%, 12/37; P = .002) than the withdrawal group. Histologic activity (hazard ratio [HR], 15.5; 95% confidence interval [CI], 1.6-146.5; P = .02) and prior anti-tumor necrosis factor exposure (HR, 6.5; 95% CI, 1.3-33.8; P = .03) predicted clinical relapse after thiopurine withdrawal. CONCLUSIONS: Thiopurine withdrawal did not affect vedolizumab trough concentrations. However, it may increase fecal calprotectin, histologic, and histo-endoscopic activity. Histologic activity and prior anti-tumor necrosis factor exposure may predict disease relapse on thiopurine withdrawal for patients using vedolizumab for UC. Australian and New Zealand Trial Registry, number ACTRN12618000812291.
引用
- Pudipeddi A, Paramsothy S, Kariyawasam V, et al. Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2024. PMID: 38729400. doi:10.1016/j.cgh.2024.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。